Swift Biosciences recently launched myT KRAS, the third product in its myT Primer menu of reagents to detect cancer mutations.

The myT KRAS kit provides 1 percent sensitivity for seven key mutations in codons 12 and 13 with little or no breakthrough from wild type, resulting in an assay with a definitive yes/no answer over a wide dynamic range, Swift said.

The assay works well with both frozen and formalin-fixed, paraffin-embedded samples, and each package includes sufficient reagents to test 30 samples, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.